Dr. Burris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
250 25th Ave N
Ste 100
Nashville, TN 37203Phone+1 615-320-5090
Education & Training
- San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1988 - 1991
- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1985 - 1988
- University of South Alabama College of MedicineClass of 1985
Certifications & Licensure
- TN State Medical License 1997 - 2025
- TX State Medical License 1991 - 2025
- PA State Medical License 1988 - 1994
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2010
Clinical Trials
- Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer Start of enrollment: 2001 Apr 01
- Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer Start of enrollment: 2000 Nov 01
- Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors Start of enrollment: 2002 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 552 citationsPhase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C. Bendell, Jordi Rodon, Howard A. Burris, Maja J.A. de Jonge, Jaap Verweij
Journal of Clinical Oncology. 2012-01-20 - 9 citationsRelative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumorsDonna S. Cox, Alicia Allred, YanYan Zhou, Jeffrey R. Infante, Michael S. Gordon
Clinical Pharmacology in Drug Development. 2015-07-01 - 2050 citationsCombined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsKeith T. Flaherty, J. R. Infante, Adil Daud, Rene Gonzalez, Richard F. Kefford
The New England Journal of Medicine. 2012-10-31
Lectures
- Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Most Patients Should Be Tested2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- 7th Community Oncology ConferenceGlobal Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012
Press Mentions
- Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19May 29th, 2020
- New Drugs Make Headway Against Lung, Prostate, Colon CancersMay 29th, 2020
- Patients with Certain Cancers Are Nearly Three Times as Likely to Die of Covid-19, Study SaysApril 28th, 2020
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: